High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis

2007514 citationsJournal Article

Authors

Arnaud Jaccard · Centre Hospitalier Universitaire de Limoges

Philippe Moreau · Centre Hospitalier Universitaire de Nantes

Véronique Leblond · Sorbonne Université

Xavier Leleu · Centre Hospitalier Universitaire de Lille

Lotfi Benboubker · Centre Hospitalier Universitaire de Tours

Olivier Hermine · Assistance Publique – Hôpitaux de Paris

Christian Récher

Abstract

The outcome of treatment of AL amyloidosis with high-dose melphalan plus autologous stem-cell rescue was not superior to the outcome with standard-dose melphalan plus dexamethasone. (ClinicalTrials.gov number, NCT00344526 [ClinicalTrials.gov].).

Topics & Keywords

Amyloidosis: Diagnosis, Treatment, Outcomes Myeloproliferative Neoplasms: Diagnosis and Treatment Coagulation, Bradykinin, Polyphosphates, and Angioedema

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 357, Issue 11, pp. 1083-1093

DOI: 10.1056/nejmoa070484

Field-Weighted Citation Impact: 14.40